Drug intelligence / Profile preview

UGXXX

Development stage: Preclinical
Lead developer: UgeneX Therapeutics
Modality: Gene Therapies
Administration: Ophthalmic

Overview

UGXXX is an investigational gene therapy candidate being developed by Suzhou Xingming Youjian Biotechnology (also known as U-Genex) for the treatment of ophthalmic and retinal diseases. Currently in the preclinical research phase, UGXXX is part of the company's pipeline of adeno-associated virus (AAV) vector-based therapies designed to address degenerative retinal conditions. While specific molecular targets and indications for this asset have not been publicly disclosed, it is being developed alongside other candidates for conditions such as retinitis pigmentosa and age-related macular degeneration. The therapy aims to deliver functional genetic material to retinal cells to restore or preserve vision in patients with high unmet clinical needs.

Other names: U-Genex gene therapy

Beyond the preview

Go deeper on UGXXX.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on UGXXX.

Explore the full profile